1. Introduction {#sec1}
===============

MicroRNAs (miRNAs), which are a new class of small noncoding RNAs (21--23 nucleotides), have emerged as crucial players regulating the magnitude of gene expression in a variety of organisms \[[@B1], [@B2]\]. Regulation of microRNAs is achieved via binding to the 3′ untranslated regions (3′ UTR) of target mRNAs, which leads to their inhibition of the expression of target genes in the translation level \[[@B3]\]. Mounting evidence suggests that microRNAs play crucial and complex roles in the initiation and progression of cancer \[[@B4]\], including cell proliferation, differentiation, apoptosis, and metabolism \[[@B5], [@B6]\]. Obviously, microRNAs may be exploited as new promising molecular biomarkers for early diagnosis and efficient treatment in human cancers \[[@B7]\].

MicroRNA-126 (miR-126), located within the 7th intron of*EGFL7* (epidermal growth factor-like domain 7), plays an important role in cellular biology, including cancer biology \[[@B8], [@B9]\]. Many studies have demonstrated that miR-126 contributes to progression of angiogenesis, proliferation, migration, invasion, and cell survival in some cancers \[[@B8], [@B10]--[@B12]\]. As a tumor suppressor, miR-126 was shown to downregulate expression in lung, breast, gastric, colon, pancreatic, oral, and some other cancers in previous studies \[[@B13]--[@B18]\]. Cancer patients with lower expression of miR-126 always had a worse prognostic outcome; however, the results from different studies indicated that miR-126 functioned as an oncogene and its expression was upregulated \[[@B19]--[@B22]\].

The majority of cancers at the time of initial diagnosis are often at an advanced stage and have poor prognosis, and therefore there is an urgent need for the identification of novel prognostic and predictive biomarkers to improve treatment of patients with various cancers \[[@B23]\]. In spite of some contradictory results, miR-126 is still a significant tumor biomarker and a potential therapeutic target \[[@B24]\]. Moreover, the result from individual study is inadequate to evaluate whether miR-126 can be considered as a promising biomarker. So we performed this meta-analysis to assess the prognostic value of tissue and blood-based miR-126 levels in various cancers.

2. Materials and Methods {#sec2}
========================

This meta-analysis was performed following the guidelines of the Systematic Reviews and Meta-Analyses (PRISMA) and the Observational Studies in Epidemiology group (MOOSE) \[[@B25]\].

2.1. Search Strategy {#sec2.1}
--------------------

Literatures were systematically searched through PubMed, Embase, the Cochrane Library, CNKI (China National Knowledge Infrastructure), and Wan Fang databases up to March 2015 without any language restrictions by two independent reviewers (Jie Bu and Hui Li). The search strategy of key words and their combination was the following terms: "microRNA-126 OR miR-126 OR miR-126-3p" AND "tumor OR tumour OR neoplasm OR cancer OR carcinoma" AND "prognosis OR survival OR outcome OR prognostic." We also carefully performed a manual search in order to identify other potentially eligible studies.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The eligible studies in this systematic review must meet all the following criteria: (1) patients are included with any type of cancers, (2) the association between miR-126 expression and survival outcome was measured in cancerous tissues or circulatory system, and (3) sufficient data was provided to calculate the hazard ratio (HR) and 95% confidence intervals (CIs). Articles were excluded according to the following criteria: (1) letters, case reports, reviews, conference abstracts, and animal or laboratory studies, (2) studies analyzing a set of miRNAs altogether and nondichotomous miR-126 expression levels, and (3) studies with fewer than 30 patients. When the same patient cohort was reported from multiple published data, only the most recent or complete study was selected.

2.3. Quality Assessment and Data Extraction {#sec2.3}
-------------------------------------------

Quality assessment of included studies was assessed by two researchers independently (Jie Bu and Hui Li) following a critical review checklist of the Dutch Cochrane Centre proposed by MOOSE \[[@B25]\]. The following items were included: first author\'s name, publication year, country or area of origin, cancer type, sample type, TNM stage, method, total number of patients, cut-off value, follow-ups and HRs of miR-126 for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS), with their 95% confidence intervals (CIs). Disagreements were resolved by discussion between these reviewers (Jie Bu, Hui Li, and Xiao-yang Li) or consultation with senior reviewer (Li-hong Liu). If both univariate and multivariate analysis results were reported for survival, the latter ones would be selected \[[@B26], [@B27]\].

We extracted the statistical variables according to the following methods. If HRs and 95% CIs were described in publications, we extracted them directly. Otherwise, survivals and deaths at specified times in each group were extracted to calculate HRs. If only Kaplan-Meier curves are available, they were extracted from the graphical survival plots to estimate the HRs following the previously described method \[[@B28], [@B29]\]. We used Engauge Digitizer version 4.1 to extract the data from Kaplan-Meier survival curves, and three independent researchers (Jie Bu, Hui Li, and Xiao-yang Li) read the curves to reduce reading variability. We also contacted the authors of eligible articles by email for additional information and the essential data needed for the meta-analytic calculations.

2.4. Statistical Analysis {#sec2.4}
-------------------------

HRs with their 95% CIs were combined to evaluated the effect of miR-126 expression on the survival outcome of cancer. Patients with overexpression of miR-126 indicated a better prognosis if HR \< 1 and its 95% CI did not overlap with 1. Heterogeneity of pooled HRs was carried out using Cochran\'s *Q*-test and Higgins *I*-square (*I* ^2^) statistic \[[@B30], [@B31]\]. If there was significant heterogeneity (*P* \< 0.05 or *I* ^2^ \> 50%.), the random-effects model (Der Simonian and Laird method) was used \[[@B32]\]. Otherwise, a fixed-effects model (Mantel-Haenszel test) was applied \[[@B33]\]. Subgroup analysis and metaregression were further performed to explore possible explanations for heterogeneity. Begg\'s funnel plot and Egger\'s bias were used to evaluate the potential publication bias \[[@B34], [@B35]\]. Analysis of sensitivity was performed to evaluate the stability of the results. All statistical tests were two-sided, and *P* \< 0.05 was regarded as statistically significant. All analyses were conducted using the Cochrane Collaboration RevMan 5.2 or STATA package version 12.0 (Stata Corporation, College Station, Texas, USA).

3. Results {#sec3}
==========

3.1. Eligible Studies and Characteristics {#sec3.1}
-----------------------------------------

A flowchart of detailed searching process is illustrated in [Figure 1](#fig1){ref-type="fig"}. Using the described searching strategy above, a total of 549 articles were initially retrieved out of PubMed, Embase, the Cochrane Library, CNKI, and Wan Fang databases. After manually screening the titles, publication types, and abstracts and then checking the full texts by two investigators (Jie Bu and Hui Li), 30 articles were selected for the present meta-analysis \[[@B36]--[@B65]\]. Among these eligible studies, 20 studies evaluated the prognostic effect of miR-126 for OS, 8 studies for DFS, and 6/4/3 studies for PFS/RFS/DSS.

The main characteristics and basic information of eligible studies were listed in [Table 1](#tab1){ref-type="table"} and Table S1 (in Supplementary Material available online at <http://dx.doi.org/10.1155/2015/739469>). A total of 4497 patients from the United States \[[@B63], [@B65]\], Spain \[[@B53]\], Japan \[[@B36], [@B37], [@B57]\], China \[[@B43]--[@B48], [@B51], [@B52], [@B58], [@B62], [@B64]\], South Korea \[[@B41]\], Netherlands \[[@B38]\], Norway \[[@B40]\], France \[[@B39]\], Bosnia and Herzegovina \[[@B42]\], Serbia \[[@B42]\], Denmark \[[@B49], [@B50], [@B54]--[@B56]\], Sweden \[[@B55]\], Canada \[[@B61]\], and Germany \[[@B59], [@B60]\] were diagnosed with a wide range of carcinomas, including acute myeloid leukemia \[[@B36], [@B38]\], adult T-cell leukemia \[[@B37]\], non-small cell lung cancer \[[@B39]--[@B44]\], colorectal cancer \[[@B49], [@B50], [@B52], [@B54]--[@B56]\], laryngeal squamous cell carcinoma \[[@B48]\], esophageal squamous cell cancer \[[@B63]\], hepatocellular carcinoma \[[@B45], [@B46]\], colon cancer \[[@B51], [@B53]\], cervical cancer \[[@B47]\], prostate cancer \[[@B58]\], oral cancer \[[@B57]\], breast cancer \[[@B59]\], clear cell renal cell carcinoma \[[@B60], [@B61]\], esophageal squamous cell carcinoma \[[@B62]--[@B64]\], and glioblastoma multiforme \[[@B65]\]. The sample size ranged from 35 to 560. The expression of miR-126 was most often examined in cancerous tissue, while 5 studies examined it in serum/plasma and 1 study tested it in bone marrow. The majority of these studies assessed miR-126 expression by quantitative real-time PCR (qRT-PCR), and in situ hybridization (ISH) was applied in six studies. The most frequently used cut-off value was the median which was applied in 19 studies and the other values were different.

3.2. OS Associated with miR-126 Expression {#sec3.2}
------------------------------------------

The main results of this meta-analysis were displayed in [Table 2](#tab2){ref-type="table"}. 20 studies including 3232 cancer patients investigated the relationship between miR-126 expression and the prognosis. For these studies evaluating OS for miR-126, a random-effects model was utilized to calculate the pooled HR and its 95% CI due to the high heterogeneity among these studies (*I* ^2^ = 57.0%, *P* = 0.001). The result showed that high miR-126 level may predict a favorable OS with the combined HR of 0.77 (95% CI: 0.64--0.93; *P* ~heterogeneity~ = 0.001) ([Table 2](#tab2){ref-type="table"}, [Figure 2(a)](#fig2){ref-type="fig"}).

Furthermore, six subgroup analyses of overall survival were performed which stratified patients by tumor type, ethnicity, sample, assay method, analysis type, and HR estimated ([Table 2](#tab2){ref-type="table"}). Subgroup analyses by tumor type showed that high miR-126 levels were significantly associated with a favorable OS in HCC (HR = 0.65, 95% CI 0.49--0.86, *P* ~heterogeneity~ = 0.311). However, AML indicated the opposite result (HR = 1.77, 95% CI 1.15--2.72, *P* ~heterogeneity~ = 0.666). In the subgroup analyses by sample type, high miR-126 levels were predictive of better outcome OS in tissue sample (HR = 0.71, 95% CI 0.60--0.85, *P* ~heterogeneity~ = 0.01). While elevated miR-126 yielded a worse OS in circulation sample (HR = 1.65, 95% CI 1.09--2.51, *P* ~heterogeneity~   *y* = 0.647). With further analyses of studies evaluating OS by ethnicity, we found that the high expression of miR-126 was a significantly favorable predictor for OS in Asians (HR = 0.76, 95% CI 0.66--0.88, *P* ~heterogeneity~ = 0.129). Similarly, this conclusion was also found in other subgroups of qRT-PCR assay (HR = 0.72, 95% CI 0.58--0.90, *P* ~heterogeneity~ \< 0.001), multivariate analysis (HR = 0.81, 95% CI 0.72--0.90, *P* ~heterogeneity~ = 0.344), and HRs reported (HR = 0.78, 95% CI 0.64--0.96, *P* ~heterogeneity~ ≤ 0.001) ([Table 2](#tab2){ref-type="table"}).

3.3. DFS Associated with miR-126 Expression {#sec3.3}
-------------------------------------------

7 studies included 755 cancer patients evaluated DFS for miR-126, a fixed-effects model was used to assess the pooled effect size due to no heterogeneity among the studies (*I* ^2^ = 0%, *P* = 0.983) ([Table 2](#tab2){ref-type="table"}), and we found that high expression of miR-126 was demonstrated to predict favorable DFS in various cancer (HR = 0.64, 95% CI 0.48--0.85, *P* ~heterogeneity~ = 0.780) ([Table 2](#tab2){ref-type="table"}, [Figure 2(b)](#fig2){ref-type="fig"}).

Similar to OS analyses, we also performed subtotal investigation for DFS analyses ([Table 2](#tab2){ref-type="table"}). In the subgroup analyses by tumor type, high miR-126 levels were significantly associated with a favorable DFS in NSCLC (HR = 0.49, 95% CI 0.26--0.93, *P* ~heterogeneity~ = 0.983). And for ethnicity and analysis type, the high expression of miR-126 was still a significantly better prognosis for DFS (Asian: HR = 0.64, 95% CI 0.44--0.94; *P* ~heterogeneity~ = 0.532; Caucasian: HR = 0.63, 95% CI 0.41--0.97, *P* ~heterogeneity~ = 0.599; multivariate: HR = 0.65, 95% CI 0.45--0.94; *P* ~heterogeneity~ = 0.384; univariate: HR = 0.67, 95% CI 0.50--0.90; *P* ~heterogeneity~ \< 0.001).

3.4. PFS/RFS/DSS Associated with miR-126 Expression {#sec3.4}
---------------------------------------------------

We combined the results for PFS, RFS, and DSS together as PFS/RFS/DSS. A total of 13 studies including 2014 tumor patients focused on PFS/RFS/DSS analysis with significant heterogeneity among them (*I* ^2^ = 67.8%, *P* \< 0.001). A random-effects model was applied, and elevated expression of miR-126 was a significant predictor of favorable PFS/RFS/DSS (HR = 0.70, 95% CI 0.50--0.98, *P* ~heterogeneity~ = 0.161) ([Table 2](#tab2){ref-type="table"}, [Figure 2(c)](#fig2){ref-type="fig"}).

In the subgroup analysis of patients with tumor type, the pooled HR indicated that the high expression of miR-126 was a favorable prognostic marker in CRC (HR = 0.74, 95% CI 0.59--0.94, *P* ~heterogeneity~ = 0.108) ([Table 2](#tab2){ref-type="table"}). The same trend was found in subgroup of Asians (HR = 0.69, 95% CI 0.48--0.99, *P* ~heterogeneity~ = 0.417) ([Table 2](#tab2){ref-type="table"}).

3.5. Heterogeneity Analysis {#sec3.5}
---------------------------

Obvious heterogeneity of subjects was observed among 13 of the 30 analysis groups, as shown in [Table 2](#tab2){ref-type="table"}. We performed a meta-regression analysis to investigate the sources of this heterogeneity in the OS analysis group (*P* = 0.001, *I* ^2^ = 57%). The obvious heterogeneity was induced by tumor sample (*P* = 0.017) rather than tumor type (*P* = 0.751), miR-126 assay method (*P* = 0.306), patients origin (*P* = 0.631), cut-off values (*P* = 0.772), publication year (*P* = 0.971), and HRs estimate (*P* = 0.836).

3.6. Publication Bias and Sensitivity Analysis {#sec3.6}
----------------------------------------------

Begg\'s funnel plot and Egger\'s test were used to assess the potential publication bias of the included studies. The funnel plots of the OS, DFS, and PFS/RFS/DSS analysis based on tissue and blood miR-126 did not reveal any evidence of obvious asymmetry. Moreover, the *P* values of Egger\'s and Begg\'s tests were all greater than 0.05 in the 30 analysis groups ([Table 2](#tab2){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}, and Figures S1 and S3). Hence, there was no obvious risk of publication bias in our meta-analysis.

Furthermore, we performed sensitivity analysis to investigate the influence of each individual study on the overall meta-analysis estimate, which computes the pooled HRs by omitting one study in each turn. And there was no obvious influence of individual study on the pooled HRs ([Figure 4](#fig4){ref-type="fig"} and Figures S2 and S4).

4. Discussion {#sec4}
=============

Cancer is considered one of the leading causes of death worldwide. The occurrence of cancer is increasing because of the growth and aging of the population, as well as increasing prevalence of established risk factors \[[@B66]\]. Despite the advances in technology and its access, to date, there are few defined prognostic and diagnostic biomarkers available in cancers. Essentially, high cancer mortality rates have remained high, mainly due to the late diagnosis and lack of prognostic markers for various cancers \[[@B67]\]. Hence, many research groups are carrying out studies to develop biomarkers, which can be applied to early detection and correlation of treatment efficacy and prognosis \[[@B68]\].

MiR-126, which is highly expressed in vascular endothelial cells, is one of the most commonly observed cancer-related microRNAs and is dysregulated in most cancers. As one of the major targets of miR-126,*EGFL7* is known to be involved in cell migration and the process of angiogenesis. The conclusion suggests that one of the main functions of miR-126 is to inhibit angiogenesis to reduce blood vessels, which is facilitated by cell migration \[[@B69], [@B70]\]. Additionally, previous studies have demonstrated that miR-126 may play a role in tumorigenesis and growth by regulating the vascular endothelial growth factor (*VEGF*)/phosphoinositol 3-kinase (*PI3K*)/*AKT* signaling pathways \[[@B43], [@B71]\]. miR-126 also maintains its role as a suppressor of metastasis that could reduce metastatic rate and size of carcinoma \[[@B14], [@B72]\]. Furthermore, interactions of miR-126 and*ADAM9* are related to epithelial-mesenchymal transition and the invasive growth of pancreatic cancer cells \[[@B73]\]. In most of the cancers studied, miR-126 functioned as a tumor suppressor and its expression was suppressed; however, several reports using different types of samples have described an oncogenic role for miR-126. Notably, several studies have shown that miR-126 is upregulated in some malignancies due to high tissue specificity, such as gastric cancer, liver cancer, ovarian cancer, and acute myeloid leukaemia \[[@B19], [@B20], [@B74], [@B75]\]. In addition, miR-126 acting as an oncogene, which was found to downregulate*HOXA9*/*PLK*, was often upregulated in myeloid leukaemia and associated with poor prognosis \[[@B22], [@B76]\]. Moreover, higher expression of miR-126 was shown to be a poor prognostic factor in NSCLC and promote metastasis in prostate cancer \[[@B77], [@B78]\]. Obviously, it is controversial that miR-126 expression can be used as a prognostic biomarker in different cancers. Hence, in order to evaluate the prognostic role of miR-126 expression in various cancers, we systematically reviewed the published studies and performed a meta-analysis for the first time.

In terms of this, a total of 4497 participants from 30 studies finally were included into the meta-analysis. This result showed that high expression of miR-126 was a significant marker for predicting better outcomes of various cancers (HR was 0.77, 0.64, and 0.70 for OS, DFS, and RFS/PFS/DSS, resp.). For OS, stratified analyses displayed that high expression of miR-126 was a better prognostic marker in HCC, Asians, tissue sample, qRT-PCR assay, multivariate analysis, and HRs reported. However, AML and circulation sample indicated the opposite result. For DFS, subgroup analyses revealed that high expression of miR-126 could predict a favorable DFS in NSCLC, Asian, Caucasian, multivariate, and univariate subgroups. Furthermore, we found that high expression of miR-126 significantly relates to a favorable RFS/PFS/DSS in CRC and Asian subgroup, but no statistical significance is shown in NSCLC, Caucasian, multivariate, and univariate analysis. Additionally, there was no obvious risk of publication bias in our meta-analysis. From the above results, we found that high expression of tissue miR-126 was a positive prognostic factor in cancer patients. But high circulating miR-126 levels predicted a significantly worse OS in patients with cancer. As we know, circulating samples are more convenient to collect and keep monitored, which can effectively evaluate prognosis during or after clinical therapy. Therefore, circulating miR-126 may be an efficacious method for dynamically monitoring the prognosis and therapeutic effects in cancer patients. In this study, only four studies investigated circulating samples, and more studies on these cancers are needed in the future.

Although the present meta-analysis revealed that the expression of miR-126 in cancer patients could be a valuable prognostic biomarker for patients, some limitations should be noticed. Firstly, there was significant heterogeneity existing in our meta-analysis, which was probably attributed to the differences in baseline demographic characters of population, characteristics of patients, the types of cancer, the samples of cancer, the disease stages, the cut-off criteria, the duration of follow-up, and so on. Secondly, several HRs were calculated based on the data extracted from the survival curve; some minor differences exist between the exact HRs and the extrapolated data. Thirdly, due to the lack of a unified cut-off value in miR-126 expression, cut-off values were not consistent among included studies. The different cut-off values may influence the availability of miR-126 as a prognostic biomarker in human cancer. Fourth, in subgroup analyses by sample type and subtype analyses, the number of studies was relatively small. More studies on these cancers are needed in the future. Finally, treatments may influence the expression of miR-126 in cancer samples; however, few researches referred to the treatment effect on HRs or miR-126 expression.

5. Conclusion {#sec5}
=============

In sum, in this meta-analysis, we concluded that overexpression of miR-126 was effectively predictive of better prognosis in various carcinomas. Increased miR-126 level in cancerous tissues was associated with favorable OS, DFS, and PFS/RFS/DSS, while elevated circulating miR-126 was indicative of poor OS. However, our results should be regarded cautiously due to the limitations of the present analysis listed above. Further prospective multicenter studies with larger sample size are needed to focus on the relationship between miR-126 and cancer prognosis as well as to explore effective therapies.
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###### 

Main characteristics of enrolled studies in the systematic review.

  Author                          Year   Country          Cancer            Number       Specimen      Assay     Cut-off value          Source of HR   Endpoint            Median follow-up (months)
  ------------------------------- ------ ---------------- ----------------- ------------ ------------- --------- ---------------------- -------------- ------------------- ---------------------------
  Shibayama et al. \[[@B36]\]     2015   Japan            AML               108          Bone marrow   qRT-PCR   Median                 R              OS                  NR
  Ishihara et al. \[[@B37]\]      2012   Japan            ATL               35           Plasma        qRT-PCR   Median                 SC             OS                  NR
  de Leeuw et al. \[[@B38]\]      2014   Netherlands      AML               92           Blood         qRT-PCR   Median                 R              OS, EFS, RFS        NR
  Sanfiorenzo et al. \[[@B39]\]   2013   France           NSCLC             52           Plasma        qRT-PCR   Median                 R              DFS                 46
  Donnem et al. \[[@B40]\]        2011   Norway           NSCLC             332          Tissue        ISH       Expression score ≥ 2   R              DSS^a^              86
  Kim et al. \[[@B41]\]           2014   South Korea      NSCLC             72           Tissue        qRT-PCR   Median                 R              OS                  31
  Jusufović et al. \[[@B42]\]     2012   Serbia           NSCLC             50           Tissue        qRT-PCR   Median                 R              OS, PFS             5.13
  Yang et al. \[[@B43]\]          2012   China            NSCLC             442          Tissue        qRT-PCR   Median                 R              OS                  24.39--29.28
  Li et al. \[[@B44]\]            2014   China            NSCLC             49           Tissue        qRT-PCR   Median                 SC             OS, DFS             39
  Han et al. \[[@B45]\]           2012   China            HCC               105          Tissue        qRT-PCR   Fold change = 2        R              OS                  42.89
  Chen et al. \[[@B46]\]          2013   China            HCC               68           Tissue        qRT-PCR   0.70 (ROC curve)       SC             OS                  49
  Yang et al. \[[@B47]\]          2014   China            Cervical cancer   133          Tissue        qRT-PCR   Median                 R              OS                  60 (max)
  Sun et al. \[[@B48]\]           2014   China            LSCC              38           Plasma        qRT-PCR   Median                 SC             OS                  NR
  Hansen et al. \[[@B49]\]        2012   Denmark          CRC               89           Tissue        ISH       Median                 SC             PFS                 16.8--26.2
  Hansen et al. \[[@B50]\]        2014   Denmark          CRC               63           Plasma        qRT-PCR   Median                 R              PFS                 8.8--9.2
  Li et al. \[[@B51]\]            2013   China            Colon cancer      53           Tissue        ISH       0/1--3+                SC             OS                  45.66--55.04
  Liu et al. \[[@B52]\]           2014   China            CRC               92           Tissue        qRT-PCR   Median                 SC             OS                  65
  Díaz et al. \[[@B53]\]          2008   Spain            Colon cancer      110          Tissue        qRT-PCR   Median                 R              OS, DFS             68
  Hansen et al. \[[@B54]\]        2011   Denmark          CRC               81           Tissue        ISH       Median                 R              OS, PFS             NR
  Hansen et al. \[[@B55]\]        2013   Denmark/Sweden   CRC               89           Tissue        qRT-PCR   Median                 R              PFS                 NR
  Hansen et al. \[[@B56]\]        2015   Denmark          CRC               560          Tissue        qRT-PCR   Median                 R              OS, DSS             7 years (max)
  Sasahira et al. \[[@B57]\]      2012   Japan            Oral cancer       94           Tissue        qRT-PCR   Means                  R              DFS                 3.4 years
  Sun et al. \[[@B58]\]           2013   China            Prostate cancer   128          Tissue        qRT-PCR   Median                 SC             RFS                 3--10 years
  Hoppe et al. \[[@B59]\]         2013   Germany          Breast cancer     80           Tissue        qRT-PCR   6.20 (ROC curve)       R              RFS                 8.84 years
  Vergho et al. \[[@B60]\]        2014   Germany          cRCC              37           Tissue        qRT-PCR   3.57 (ROC curve)       R              DSS                 41.4
  Khella et al. \[[@B61]\]        2015   Canada           cRCC              257,481^b^   Tissue        qRT-PCR   20th percentile        R              OS, DFS, OS^b^      48.6
  Liu et al. \[[@B62]\]           2015   China            ESCC              185          Tissue        ISH       Fold change \> 3       R              DSS                 32
  Hu et al. \[[@B63]\]            2011   USA              ESCC              158          Tissue        ISH       1--3+/0--0.5           R              OS, DFS             16.25
  Wang et al. \[[@B64]\]          2013   China            ESCC              116          Tissue        qRT-PCR   ΔΔCT \< −1             SC             DFS                 21--32
  Feng et al. \[[@B65]\]          2012   USA              GBM               248          Tissue        qRT-PCR   Median                 R              PFS/RFS^b^, OS^b^   NR

CRC: colorectal cancer; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; cRCC: clear renal cell carcinoma; ESCC: esophageal squamous cell carcinoma; AML: acute myeloid leukemia; ATL: adult T-cell leukemia; LSCC: laryngeal squamous cell carcinoma; GBM: glioblastoma multiforme; qRT-PCR: quantitative real-time PCR; ISH: in situ hybridization; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; PFS: progression-free survival; DSS: disease-specific survival; HR: hazard ratio; SC: survival curve; NR: not reported; R: reported.

^a^DSS included any of the following: DSS, CSS (cancer-specific survival). ^b^Data extracted from TCGA (The Cancer Genome Atlas) in the paper.

###### 

Meta-analysis results.

  Outcome           Variables   Number of studies   Number of patients   Model               HR (95% CI)         Heterogeneity   Publication bias           
  ----------------- ----------- ------------------- -------------------- ------------------- ------------------- --------------- ------------------ ------- -------
  OS                All         20                  3232                 Random              0.77 (0.64, 0.93)   56.8            0.001              0.381   0.358
  *Tumor type*                                                                                                                                              
  NSCLC             4           613                 Random               0.42 (0.17, 1.08)   82.2                0.001           1.000              0.340   
  HCC               2           173                 Fixed                0.65 (0.49, 0.86)   2.60                0.311                                      
  CRC               5           896                 Fixed                0.85 (0.69, 1.04)   0                   0.584           0.806              0.679   
  RCC               2           738                 Fixed                0.65 (0.38, 1.12)   0                   0.624                                      
  AML               2           200                 Fixed                1.77 (1.15, 2.72)   0                   0.666                                      
  *Ethnicity*                                                                                                                                               
  Asian             12          1353                Fixed                0.76 (0.66, 0.88)   37.0                0.129           0.837              0.668   
  Caucasian         8           1879                Random               0.77 (0.57, 1.05)   73.8                \<0.001         0.536              0.479   
  *Sample*                                                                                                                                                  
  Circulation       4           273                 Fixed                1.65 (1.09, 2.51)   0                   0.647           0.734              0.162   
  Tissue            16          2959                Random               0.71 (0.60, 0.85)   51.1                0.01            0.137              0.068   
  *Assay method*                                                                                                                                            
  qRT-PCR           17          2940                Random               0.72 (0.58, 0.90)   61.2                \<0.001         0.303              0.250   
  ISH               3           292                 Fixed                1.00 (0.75, 1.34)   0                   0.804           1.000              0.646   
  *Analysis type*                                                                                                                                           
  Multivariate      7           1870                Fixed                0.81 (0.72, 0.90)   11.0                0.344           0.072              0.095   
  Univariate        7           1530                Random               0.89 (0.79, 1.00)   66.4                0.007           1.000              0.990   
  *HR estimated*                                                                                                                                            
  HRs reported      14          2897                Random               0.78 (0.64, 0.96)   67.8                \<0.001         0.274              0.461   
  K-M curve         6           335                 Fixed                0.79 (0.53, 1.18)   0                   0.666           1.000              0.705   
                                                                                                                                                            
  DFS               All         7                   755                  Fixed               0.64 (0.48, 0.85)   0               0.780              0.133   0.203
  *Tumor type*                                                                                                                                              
  NSCLC             2           101                 Fixed                0.49 (0.26, 0.93)   0                   0.983                                      
  ESCC              2           274                 Fixed                0.77 (0.48, 1.24)   0                   0.629                                      
  *Ethnicity*                                                                                                                                               
  Asian             4           417                 Fixed                0.64 (0.44, 0.94)   0                   0.532           0.308              0.081   
  Caucasian         3           419                 Fixed                0.63 (0.41, 0.97)   0                   0.599           1.000              0.874   
  *Analysis type*                                                                                                                                           
  Multivariate      3           509                 Fixed                0.65 (0.45, 0.94)   0                   0.384           0.296              0.360   
  Univariate        4           619                 Random               0.67 (0.50, 0.90)   88.0                \<0.001         0.734              0.586   
                                                                                                                                                            
  RFS/PFS/DSS       All         13                  2014                 Random              0.70 (0.50, 0.98)   84.8            \<0.001            0.360   0.288
  *Tumor type*                                                                                                                                              
  CRC               5           882                 Fixed                0.74 (0.59, 0.94)   47.3                0.108           1.000              0.514   
  NSCLC             2           382                 Random               0.43 (0.03, 7.25)   97.2                \<0.001                                    
  *Ethnicity*                                                                                                                                               
  Asian             2           313                 Fixed                0.69 (0.48, 0.99)   0                   0.417                                      
  Caucasian         11          1701                Random               0.69 (0.46, 1.02)   87.1                \<0.001         0.213              0.267   
  *Analysis type*                                                                                                                                           
  Multivariate      7           1531                Random               0.71 (0.50, 1.02)   83.2                \<0.001         0.230              0.281   
  Univariate        5           651                 Random               0.89 (0.77, 1.02)   81.4                \<0.001         0.462              0.872   

CRC: colorectal cancer; HCC: hepatocellular carcinoma, NSCLC: non-small cell lung cancer; cRCC: clear renal cell carcinoma; ESCC: esophageal squamous cell carcinoma; AML: acute myeloid leukemia; K-M curve: Kaplan-Meier curve; fixed: fixed-effects model; random: random-effects model.

[^1]: Academic Editor: Sheng Pan
